



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

16 July 2020

Four US university hospitals deploy GMV's Independent Diagnostic Testing Facilities (IDTF) platform

- Institutional deployment of GMV's IDTF platform is expected to generate increased patient numbers and revenue (CY2019 revenue from IDTF was US\$5.42m)
- To date, the majority of IDTF revenue has been sourced through smaller healthcare facilities – hospital implementation is a key catalyst to scale patient numbers; three-fold increase in patient numbers expected by end CY2020 based on current activities (CY2019: 27,946 patients monitored)
- New university hospitals have already enrolled ~2,000 patients which are currently and will progressively undergo various cardiac and remote monitoring modalities
- More US hospitals being pursued with further implementations expected near-term

Medical device and telehealth company **G Medical Innovations Holdings Ltd (ASX: GMV)** ("G Medical" or "Company") is delighted to report that four hospitals affiliated with leading universities in the United States of America have implemented GMV's Independent Diagnostic Testing Facilities (IDTF) platform (through the Company's wholly owned subsidiary G Medical Diagnostic Services Inc. (GMEDx), so patients and outpatients of these hospitals can use the cardiac and remote monitoring technologies.

This is a major achievement for GMV and is the culmination of a comprehensive business development and evaluation program by the hospitals which commenced at the beginning of 2020. Implementation with these hospitals is expected to lead to an increase in patient numbers and thus revenue. Revenue from new enrolments is expected to be progressively booked over the next 90 days. Once patients are enrolled, they commence an individualised monitoring service ranging from a 24-hour period to 30 days or longer, including Mobile Cardiac Telemetry (MCT), Holter monitoring, Ambulatory electrocardiography (AECG).

Already, ~2,000 patients from the four hospitals have been referred and this will continue to grow. A substantial number of hospitals that deploy IDTF are expected to be progressively added in the US and GMV is pursuing other opportunities for IDTF in other markets outside of the US.

As well, the new hospitals provide G Medical with a potential sales channel for its medical devices including its FDA approved Prizma medical device. The Company will gradually increase its sales force to provide for a continued increase in patient enrolments and as additional opportunities from the new hospitals arise.

CEO Dr Yacov Geva, said: *"The implementation of IDTF in these first four US hospitals is an excellent development for GMV and a great endorsement of our cardiac and remote patient monitoring services."*

"To date, IDTF has predominately been made available through doctors clinics, cardiologists, electro-physiologists and internists. Hospital deployments will be a major revenue driver for us and provide an excellent foundation to promote and sell our own monitoring devices, specifically our Patch and Prizma, to

further augment revenue streams. I look forward to reporting back as we steadily and rapidly grow patient monitoring numbers.”

“Telehealth is a growing medium in the current market and this development is evidence of that. In very short order, we are confident that a number of new hospitals will be progressively added and this will continue to increase patient referrals.”

Ends

Authorised for release by Yacov Geva, Managing Director.

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and telehealth solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ smartphone compatible medical device is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.